## Current as of 6/1/2013. This document may not be part of the latest approved REMS.

## **REMS Prescription Authorization Form**

Please complete all sections of this form and fax it to the KYNAMRO™ REMS Program at 877-778-9008. If you have any questions, contact the KYNAMRO REMS Program at 877-596-2676.

have any questions,									
Full Name (first, middle, last	print. Ali info		mation marked with an * is required.)  Gender* — — — Date of Birth*						
Tuli Name (mst, mudie, ia.	51)			G	ender"	]M □ F		Date of Billin	
Address*			City*		State*			Zip*	
Preferred Phone Number*			Alternate Phone Number					Preferred Time to Contact	
								☐ Day ☐ Evening	
Email Address			Alternate Contact/Phone						
Shipping Information Ship to ☐ Pati			ient's Home Address (address above)			☐ Other Address (indicate below)			
Name	Address		City		State	Zip		Phone Number	
Insurance Information (Please print.)									
Primary Insurance Name					Primary Insurance Phone				
Policy Holder's Name			Policy Holder's Date of Birth		Relation		tionsh	ship to Patient	
Policy/Rx ID	Group Number								
Secondary Insurance Name				Secondary Inst			Insura	ance Phone	
Policy Holder's Name Policy H				r's Date of Birth Relations			tionsh	ip to Patient	
Policy/Rx ID	Group Number								
Prescription Card				(complete information below)					
Carrier	ID# Policy/Group		# Cardholder's		s Full Name			Cardholder's Date of Birth	
Pro	scribor Informa	ation (Bloase	o print All in	oformation :	markod	with an	* ic r	oquired )	
Prescriber Information (Please print. All information marked with an * is required.)  Prescriber's Full Name*  NPI*									
Phone Number*				Fax Number*					
Practice Street Address*			City*	State*			Zip*		
density lipoprotein- lipoprotein-choleste ✓I affirm that my pat ✓I understand that k ✓I attest that I have Prescribing Informa	(YNAMRO is ir -cholesterol (LI erol (non-HDL-tient has a clini (YNAMRO has obtained the liver)	ndicated as DL-C), apol ·C) in patier cal or labor inot been a ver-related	ipoprotein B nts with hom atory diagno adequately s laboratory to	B (apo B), to nozygous fa osis consist studied in pe ests for this	otal cho imilial h ent with ediatric patien	lesterol ( hypercho h HoFH. patients t as direc	(TC) leste s less cted	s than 18 years of age. in the KYNAMRO	
Dosing Instructions*	runto i resemp	Alon (nacco		normation i	нагиси	Refills		1 2 3 4 5 6	
							1117	1 2 3 4 3 0	

The KYNAMRO Prescription Authorization Form is available at <a href="https://www.KynamroREMS.com">www.KynamroREMS.com</a>

PRESCRIBER SIGNATURE\*

□Dispense as Written

DATE\*